Mit Lesen beginnen

Diabetes Core Update – January 2018: Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes...

Bewertung:
0 Seite

Zusammenfassung

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 20 minutes and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. This month we review articles on: Linagliptin Cardiovascular Outcome Trial (CARMELINA) Aspirin for Primary Prevention in Diabetes Dapagliflozin Cardiovascular Outcome Trial (DECLARE-TIMI) Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia Lorcaserin and Prevention and Remission of Type 2 Diabetes Albiglutide Cardiovascular Outcome Trial (HARMONY) SGLT-2 Inhibitors for prevention of Cardiovascular and Renal Outcomes For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Abington Jefferson Health

Auf der mobilen App von Scribd lesen

Die kostenlose mobile App von Scribd herunterladen, um überall und überall zu lesen.